Teva reports positive Phase 2a topline celiac disease results
Teva said its Phase 2a study in celiac disease for its anti-IL-15 antibody delivered positive topline results, further validating its pipeline-in-a-product potential.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.